145 related articles for article (PubMed ID: 38839689)
21. [Chemoradiotherapy for esophageal cancer: real results and immediate perspectives].
Tiuriaeva EI; Kanaev SV
Vopr Onkol; 2012; 58(3):312-9. PubMed ID: 22888644
[No Abstract] [Full Text] [Related]
22. [Therapeutic strategies for advanced respectable esophageal cancer].
Kitagawa Y
Nihon Geka Gakkai Zasshi; 2008 Nov; 109(6):333-7. PubMed ID: 19068714
[TBL] [Abstract][Full Text] [Related]
23. Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
Pucher PH; Rahman SA; Walker RC; Grace BL; Bateman A; Iveson T; Jackson A; Rees C; Byrne JP; Kelly JJ; Noble F; Underwood TJ
Eur J Surg Oncol; 2020 Dec; 46(12):2248-2256. PubMed ID: 32694054
[TBL] [Abstract][Full Text] [Related]
24. Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus.
Ilson DH; van Hillegersberg R
Gastroenterology; 2018 Jan; 154(2):437-451. PubMed ID: 29037469
[TBL] [Abstract][Full Text] [Related]
25. Triple-modality therapy for a woman with locally advanced thoracic esophageal adenocarcinoma, Part 2.
Schefter TE; Patel M; McCarter M; Kane M; Russ PD; Nash SR; Shah RJ; Mitchell JD
Oncology (Williston Park); 2005 Jun; 19(7):830, 835-6, 838 passim. PubMed ID: 16053033
[No Abstract] [Full Text] [Related]
26. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial.
von Döbeln GA; Klevebro F; Jacobsen AB; Johannessen HO; Nielsen NH; Johnsen G; Hatlevoll I; Glenjen NI; Friesland S; Lundell L; Yu J; Nilsson M
Dis Esophagus; 2019 Feb; 32(2):. PubMed ID: 30137281
[TBL] [Abstract][Full Text] [Related]
27. Definitive chemoradiotherapy for esophageal carcinoma.
Cooper SL; Russo JK; Chin S
Surg Clin North Am; 2012 Oct; 92(5):1213-48. PubMed ID: 23026279
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.
Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906
[TBL] [Abstract][Full Text] [Related]
29. Importance of residual primary cancer after induction therapy for esophageal adenocarcinoma.
Raja S; Rice TW; Ehrlinger J; Goldblum JR; Rybicki LA; Murthy SC; Adelstein D; Videtic G; McNamara MP; Blackstone EH
J Thorac Cardiovasc Surg; 2016 Sep; 152(3):756-761.e5. PubMed ID: 27530636
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
31. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
32. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
[TBL] [Abstract][Full Text] [Related]
33. [Current surgical treatment and perspectives for esophageal cancer].
Tsubosa Y
Nihon Shokakibyo Gakkai Zasshi; 2014 Feb; 111(2):269-75. PubMed ID: 24500316
[No Abstract] [Full Text] [Related]
34. Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.
Mantziari S; Gronnier C; Renaud F; Duhamel A; Théreaux J; Brigand C; Carrère N; Lefevre JH; Pasquer A; Demartines N; Collet D; Meunier B; Mariette C;
Ann Surg; 2017 Nov; 266(5):805-813. PubMed ID: 28742698
[TBL] [Abstract][Full Text] [Related]
35. Outcomes With Open and Minimally Invasive Ivor Lewis Esophagectomy After Neoadjuvant Therapy.
Tapias LF; Mathisen DJ; Wright CD; Wain JC; Gaissert HA; Muniappan A; Lanuti M; Donahue DM; Morse CR
Ann Thorac Surg; 2016 Mar; 101(3):1097-103. PubMed ID: 26652140
[TBL] [Abstract][Full Text] [Related]
36. [New aspects of neoadjuvant therapy of malignant tumors of the upper gastrointestinal tract].
Mönig SP; Berlth F; Chon SH
Zentralbl Chir; 2014 Dec; 139(6):569-71. PubMed ID: 25674647
[No Abstract] [Full Text] [Related]
37. Choosing the best treatment for esophageal cancer : criteria for selecting the best multimodal therapy.
Hölscher AH; Bollschweiler E
Recent Results Cancer Res; 2012; 196():169-77. PubMed ID: 23129373
[TBL] [Abstract][Full Text] [Related]
38. Does Neutrophil-to-Lymphocyte Ratio (NLR) Predict Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma?
Anand S; Bhati G; Gurram R; Gnanasekaran S; Kate V; Pottakkat B; Kalayarasan R
J Gastrointest Cancer; 2021 Jun; 52(2):659-665. PubMed ID: 32607960
[TBL] [Abstract][Full Text] [Related]
39. Management of advanced-stage operable esophageal cancer.
Bharat A; Crabtree T
Surg Clin North Am; 2012 Oct; 92(5):1179-97. PubMed ID: 23026277
[TBL] [Abstract][Full Text] [Related]
40. The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of oesophageal cancer.
Veuillez V; Rougier P; Seitz JF
Best Pract Res Clin Gastroenterol; 2007; 21(6):947-63. PubMed ID: 18070697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
